Loading…
Employees: 67
Size Prothena (PRTA) is a United States Health Care company (Biotechnology) with a market value of $409M, the 2842nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.97 on 6 Nov 2026.
Performance Over six months the shares fell 25.7%, against -18.2% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 427.3% over the last twelve months (peer median +12.9%); the operating margin is -109.8% (peer median -4.4%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 5.3× (5th cheapest of 17).
Short interest Short interest is 15.5% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $54.5M | $9.68M | $135M | $91.4M | $53.9M |
| Revenue growth | — | -93% | +48% | +70% | — |
| Gross profit | $50.8M | $5.98M | $132M | $83.0M | $47.2M |
| EBITDA | -$56.2M | -$181M | -$151M | -$183M | -$125M |
| Net income | -$44.0M | -$244M | -$122M | -$147M | -$117M |
| Free cash flow | -$62.1M | -$164M | -$150M | -$137M | -$109M |
| Capital expenditure | $659,372 | $138,000 | $298,000 | $2.81M | $464,000 |
| Total debt | $6.99M | $8.37M | $10.8M | $11.8M | $6.47M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRTA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -8.5% | 10th highest of 21 |
| 6-month return | -25.7% | -18.2% | 9th lowest of 21 |
| Distance from 52-week high | -32.5% | -44.7% | 7th highest of 21 |
| Revenue growth (TTM) | +427.3% | +12.9% | 2nd highest of 18 |
| Operating margin | -109.8% | -4.4% | 6th lowest of 18 |
| EV / Sales | 2.4× | 5.3× | 5th cheapest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |